<DOC>
	<DOCNO>NCT00453180</DOCNO>
	<brief_summary>The purpose study determine whether treatment oral N-acetylcysteine ( NAC ) improve behavior problem often associate autism spectrum disorder .</brief_summary>
	<brief_title>A Study Oral N-Acetylcysteine Children With Autism Spectrum Disorders</brief_title>
	<detailed_description>Autism increasingly recognize common disorder enormous public health significance . The core symptom autism include severe deficit social relatedness communication , interfere repetitive behavior . No medication show consistently improve symptom . The central hypothesis study NAC improve behavioral manifestation autism may include core associate symptom . We plan test hypothesis complete objective project pursue follow specific aim : - Evaluate efficacy oral NAC 12-week , double-blind , placebo-controlled study involve 32 child adolescent autism spectrum disorder . - Evaluate safety tolerability oral NAC 32 child adolescent autism spectrum disorder .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Autism Spectrum Disorder</mesh_term>
	<mesh_term>Child Development Disorders , Pervasive</mesh_term>
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Asperger Syndrome</mesh_term>
	<mesh_term>Developmental Disabilities</mesh_term>
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<criteria>Age 4 12 year . Diagnosis autistic disorder , Asperger 's disorder , PDD NOS . If take concomitant psychotropic medication , medication must constant dose 60 day dose change plan duration trial . Able swallow capsule . Presence medical condition significantly increase risk hamper assessment ( e.g. , unstable hypertension cardiac disease , unstable asthma , kidney disease , unstable seizure disorder , pregnancy medical condition determine investigator ) . Weight &lt; 15 kg . Subjects take concomitant medication supplement know glutamatergic effect ( e.g. , dextromethorphan , Dcycloserine , amantadine , memantine , lamotrigine , riluzole ) antioxidant property ( high dose vitamin supplement , DMG , TMG , many alternative treatment ) within 30 day baseline visit exception short term use dextromethorphan need cough suppressant . The use medicine must stop least 7 day prior baseline visit . Regular multivitamin allow . Subjects take daily acetaminophen nonsteroidal antiinflammatory drug within 30 day baseline visit . Profound mental retardation evidence mental age 18 month . Subjects take concomitant medication potential pharmacokinetic pharmacodynamic drugdrug interaction ( e.g. , carbamazepine ) within 30 day baseline visit . Subjects likely experience significant change ongoing psychosocial medical treatment autism course trial ( e.g. , initiation new behavioral therapy , initiation new medication alternative treatment [ e.g. , chelation ] ) . Minor change ongoing treatment ( e.g. , missed therapy session due holiday/vacation ; plan break therapy due school holiday ) consider significant . History prior treatment NAC . Evidence hypersensitivity/allergy NAC . Presence certain neurodevelopmental disorder Fragile X Syndrome , Tuberous Sclerosis , neurological disorder know associated autism autistic feature . Diagnosis Rett 's disorder , childhood disintegrative disorder , schizophrenia , bipolar disorder , another psychotic disorder , substance abuse disorder .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Autistic Disorder</keyword>
	<keyword>Asperger 's</keyword>
	<keyword>PDD NOS</keyword>
	<keyword>Pervasive Developmental Disorder</keyword>
	<keyword>Autism</keyword>
	<keyword>N-acetylcysteine</keyword>
	<keyword>acetylcysteine</keyword>
	<keyword>NAC</keyword>
	<keyword>antioxidant</keyword>
	<keyword>treatment</keyword>
	<keyword>core symptom</keyword>
	<keyword>Autism Spectrum Disorders</keyword>
	<keyword>Asperger 's Disorder</keyword>
	<keyword>Pervasive Developmental Disorder Not Otherwise Specified</keyword>
	<keyword>Pervasive Developmental Disorders</keyword>
</DOC>